Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma (Q38618654)

4 September 2017

title

Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma (English)

1 reference

4 September 2017

L G Estévez

1

1 reference

4 September 2017

E García

series ordinal

2

1 reference

4 September 2017

M Hidalgo

series ordinal

3

1 reference

4 September 2017

publication date

28 October 2015

1 reference

Clinical and Translational Oncology

4 September 2017

published in

1 reference

4 September 2017

volume

18

1 reference

4 September 2017

issue

6

1 reference

4 September 2017

page(s)

541-549

1 reference

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

cDNA cloning of a Novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF β-receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

IRS-1 activates phosphatidylinositol 3'-kinase by associating with src homology 2 domains of p85

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Rapamycin passes the torch: a new generation of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

PI3K pathway alterations in cancer: variations on a theme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Integrated genomic characterization of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

The PIK3CA gene is mutated with high frequency in human breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

PIK3CA mutation associates with improved outcome in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Class 1A PI3K regulates vessel integrity during development and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Triple-negative breast cancer: risk factors to potential targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1410-Z

Mechanism of activation of protein kinase B by insulin and IGF-1

21 January 2018

1 reference

12 December 2020

Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes

1 reference

12 December 2020

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

1 reference

12 December 2020

Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation

1 reference

12 December 2020

Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy

1 reference

12 December 2020

10.1007/S12094-015-1410-Z

Identifiers

DOI

1 reference

4 September 2017

1 reference